Flerie Invest AB

Equities

FLERIE

SE0008966295

Pharmaceuticals

Market Closed - Nasdaq Stockholm 17:00:00 20/06/2024 BST 5-day change 1st Jan Change
0.499 SEK -2.92% Intraday chart for Flerie Invest AB -2.92% +94.92%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Alligator Bioscience Names New CFO MT
InDex Pharmaceuticals Holding AB will Change its Name to Flerie AB CI
Flerie Invest AB completed the acquisition of InDex Pharmaceuticals Holding AB (OM:INDEX) from group of shareholders. CI
InDex Pharmaceuticals Gets OK to Keep Nasdaq First North Growth Market Listing Amid Reverse Takeover, Uplisting Plans MT
Global markets live: Microsoft, Roche, BMW, Nintendo, Nordson... Our Logo
InDex Pharmaceuticals to Buy Flerie Invest Under Reverse Merger Plan MT
InDex Pharmaceuticals Holding AB Approves the Election of Karl Tobieson as Board Member CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Index Pharmaceuticals Holding AB Announces Board Resignations CI
InDex Pharmaceuticals CEO, CFO to Step Down as Operations Cease MT
Index Pharmaceuticals Holding AB Announces Resignation of Johan Giléus as Deputy CEO CI
InDex Pharmaceuticals Holding AB Announces Resignation of Jenny Sundqvist as CEO, Effective September 26, 2024 CI
InDex Pharmaceuticals Holding AB Announce Resignation of Johan Giléus as CFO, Effective September 26, 2024 CI
InDex Pharmaceuticals Launches Strategic Review Amid Decision to Stop Cobitolimod Development MT
InDex Pharmaceuticals Holding AB Discontinues the Development of Cobitolimod CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
InDex Pharmaceuticals Holding AB Discontinues Cobitolimod Phase III Program CI
InDex Pharmaceuticals Holding AB Announces Composition of the Nomination Committee CI
InDex Pharmaceuticals Obtains South Korean Patent for Inflammatory Bowel Disease Drug Candidate MT
InDex Pharmaceuticals Holding AB Receives New Patent for Cobitolimod in South Korea CI
InDex Pharmaceuticals Holding AB Announces All Patients Needed for the Cobitolimod Dose Selection Milestone Have Completed Induction Study 1 of the Phase III Program Conclude CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
InDex Pharmaceuticals Holding AB Announces Positive Results from the Pharmacokinetic (PK) Study CI
Chart Flerie Invest AB
More charts
Flerie AB, formerly InDex Pharmaceuticals Holding AB, is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is an active long-term global biotech and pharmaceutical investor that managing a portfolio of companies in Europe, Israel, and the US. Flerie invests in companies across the entire value chain, providing exposure to opportunities across three segments: Product Development, Commercial Growth, and Limited Partnerships. The Product Development segment consists of early-stage biotech and pharma companies in product development. The Commercial Growth segment consists of companies that are already selling products or services and showcasing proof-of-concept with high growth and some that have already reached profitability. The Limited Partnerships segment provides benefits for the other two segments, including co-investment opportunities, and derisks Flerie’s investment portfolio.
More about the company
  1. Stock Market
  2. Equities
  3. FLERIE Stock
  4. News Flerie Invest AB
  5. InDex Pharmaceuticals to Buy Flerie Invest Under Reverse Merger Plan